Bristol Myers Squibb (CELG-RI) EPS (Basic) (QoQ) (2009 - 2026)
Bristol Myers Squibb (CELG-RI) EPS (Basic) (QoQ) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn |
| 10 | Bristol Myers Squibb | 188.27 Mn | -10.88 Bn | 9.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.54% |
| Mar 31, 2026 | 146.20% |
| Dec 31, 2025 | -50.48% |
| Sep 30, 2025 | 67.09% |
| Jun 30, 2025 | -46.77% |
| Mar 31, 2025 | 3,133.09% |
| Dec 31, 2024 | -93.74% |
| Sep 30, 2024 | -27.89% |
| Jun 30, 2024 | 114.11% |
| Mar 31, 2024 | -791.19% |
| Dec 31, 2023 | -9.42% |
| Sep 30, 2023 | -5.26% |
| Jun 30, 2023 | -8.12% |
| Mar 31, 2023 | 13.60% |
| Dec 31, 2022 | 26.11% |
| Sep 30, 2022 | 12.53% |
| Jun 30, 2022 | 12.06% |
| Mar 31, 2022 | -44.02% |
| Dec 31, 2021 | 52.70% |
| Sep 30, 2021 | 46.80% |